Enrolment in clinical trials enhances the survival benefit provided to lung cancer patients

Clotilde Fournier (Marseille, France), Clotilde Fournier, Pascale Tomasini, Anderson Loundou, Laurent Greillier, Fabrice Barlesi

Source: International Congress 2016 – Prognostic variables in lung cancer II
Session: Prognostic variables in lung cancer II
Session type: Thematic Poster
Number: 2877
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Clotilde Fournier (Marseille, France), Clotilde Fournier, Pascale Tomasini, Anderson Loundou, Laurent Greillier, Fabrice Barlesi. Enrolment in clinical trials enhances the survival benefit provided to lung cancer patients. Eur Respir J 2016; 48: Suppl. 60, 2877

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD
Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery
Year: 2015



Clinical factors of long-term survival in patients with advanced lung cancer
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017

Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009

Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008


The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting
Source: Eur Respir J 2002; 20: Suppl. 38, 399s
Year: 2002

Chemotherapy improves low performance status lung cancer patients
Source: Eur Respir J 2007; 30: 1186-1192
Year: 2007



The evaluation of lung cancer patients
Source: Eur Respir J 2005; 26: Suppl. 49, 323s
Year: 2005

Treatment and survival in patients with pulmonary carcinoid tumours; an updated analysis from the UK national lung cancer audit
Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features
Year: 2015


Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients?
Source: Eur Respir J 2002; 19: 464-468
Year: 2002



Attempting tissue diagnosis in performance status 3 and 4 lung cancer patients may not influence treatment or survival
Source: Annual Congress 2013 –Quality management in thoracic oncology
Year: 2013



Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016


Characteristics of lung cancer patients in Serbia and subsequent treatment in advanced NSCLC over time – epidemiology study
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017

The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014

Clinical trials in advanced stage lung cancer: A survey of patients‘ opinion about their treatment
Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients
Year: 2010

Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


Lung function estimation in patients with lung cancer qualified for surgical treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 719s
Year: 2006

Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial
Source: Eur Respir J 2007; 30: Suppl. 51, 240s
Year: 2007

Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002

Reducing delays in lung cancer diagnostic pathways to improve patient experience
Source: International Congress 2016 – Quality management and quality of life in lung cancer
Year: 2016